SCHEDULE: Franklin Resources Discloses 7.7% Stake in Contineum

Franklin Resources, Inc. and its affiliates have disclosed a 7.7% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.

Summary

• Franklin Resources, Inc., along with its affiliates Charles B. Johnson, Rupert H. Johnson, Jr., and Franklin Advisers, Inc., filed an Amendment No. 2 to Schedule 13G.
• The filing reports beneficial ownership of 1,655,548 shares of Contineum Therapeutics, Inc. Class A Common Stock.
• This aggregate amount represents 7.7% of the Class A Common Stock outstanding.
• Franklin Advisers, Inc. holds sole voting and sole dispositive power over all 1,655,548 shares.
• The event requiring this filing occurred on September 30, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership. It does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• NA This filing is a disclosure of beneficial ownership and does not contain information typically categorized as 'positives' regarding company performance or operations.

Negatives

• NA This filing is a disclosure of beneficial ownership and does not contain information typically categorized as 'negatives' regarding company performance or operations.

Risks

• NA This Schedule 13G filing primarily discloses beneficial ownership and does not detail specific company risks or future challenges for Contineum Therapeutics, Inc.

Future Outlook

NA This Schedule 13G filing is a disclosure of current beneficial ownership and does not provide forward-looking statements or guidance regarding Contineum Therapeutics, Inc.'s operations or financial performance.

Management Comments

• NA This filing does not contain notable quotes or paraphrased statements from Contineum Therapeutics, Inc. management. It includes certifications from Franklin Resources, Inc. management regarding the nature of the acquisition and holding of securities.

Industry Context

This filing indicates a significant institutional investment in Contineum Therapeutics, Inc. by Franklin Resources, a major global investment management organization. Such disclosures are common in the biotechnology and pharmaceutical sectors, where institutional investors frequently take positions in companies with promising pipelines or market potential. The 7.7% stake suggests a notable, but non-controlling, interest in the company.

Comparison to Industry Standards

• NA This filing is a standard beneficial ownership disclosure (Schedule 13G) and does not present operational or financial results that can be directly compared to industry benchmarks or specific comparable companies/projects. It merely reports an ownership stake.

Management Changes

Corporate Governance

Legal Proceedings

• NA This filing does not report any litigation or regulatory matters concerning Contineum Therapeutics, Inc.

Related Party Transactions

• NA This filing does not disclose any related party dealings for Contineum Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Franklin Resources, Inc. may be viewed positively by other investors, signaling confidence in Contineum Therapeutics, Inc. However, it does not imply any change in control or operational strategy.

Next Steps

• NA This filing does not mention any specific future actions, events, or milestones for Contineum Therapeutics, Inc. or the reporting persons beyond the ongoing holding of the securities.

Key Dates

Keywords

Contineum Therapeutics, Franklin Resources, Franklin Advisers, Beneficial Ownership, Schedule 13G, Class A Common Stock, Institutional Investor, Equity Stake